Moreover, mTOR inhibition with rapamycin reduced levels of PD-L1, both in human cell lines and in murine models of NSCLC and combined treatment with rapamycin and anti-PD-1 antibody inhibited tumor growth in mice [42]. The gene discussed is PDCD1; the disease is neoplasm.